Drugs / S-892216
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07217886 | Oct 2025 → Feb 2026 | impaired renal function disease | Shionogi | Completed | No outcome recorded |
| Phase 1 | NCT07093580 | Jul 2025 → May 2027 expected | — | Shionogi | Recruiting | No outcome recorded |
| Phase 1 | NCT06751017 | Dec 2024 → Feb 2025 | COVID-19 | Shionogi | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06928051 | Jun → Sep 2025 | COVID-19 | Shionogi | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S-892216 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07217886 ↗ |
| Route | Oral | “S-892216 will be administered orally as a tablet.” NCT06751017 ↗ |